The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease
Condition: Dry Eye Disease Interventions: Drug: Topical spironolactone ophthalmic solution, 0.005 mg/cc; Drug: Placebo Sponsor: Richard W Yee, MD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials